PCN143 AN UPDATED CLINICAL-ECONOMIC MODELING ANALYSIS OF CERVICAL CANCER SCREENING WITH HPV CO-TESTING VERSUS PRIMARY HPV TESTING

Abstract

Consensus US cervical cancer screening guidelines recommend women aged 30–65 years should be screened: (1) every 5 years with high-risk HPV testing alone; or (2) every 5 years with Pap and high-risk HPV co-testing; or (3) every 3 years with Pap alone. However, nearly 1-in-5 cancers (18.6%) are missed by HPV testing alone and 12.2% of cancers are missed by Pap testing alone. Hence, co-testing is the preferred screening method. For deeper understanding, we performed updated clinical-economic comparisons of co-testing with genotyping (Co-test GT) versus primary HPV with genotyping and reflex cytology (HPV GT) for cervical cancer screening.